These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

759 related articles for article (PubMed ID: 17438315)

  • 1. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes.
    Nachega JB; Hislop M; Dowdy DW; Chaisson RE; Regensberg L; Maartens G
    Ann Intern Med; 2007 Apr; 146(8):564-73. PubMed ID: 17438315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults.
    Nachega JB; Hislop M; Dowdy DW; Gallant JE; Chaisson RE; Regensberg L; Maartens G
    AIDS; 2008 Oct; 22(16):2117-25. PubMed ID: 18832875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved virologic outcomes over time for HIV-infected patients on antiretroviral therapy in a cohort from Rio de Janeiro, 1997-2011.
    Martin DA; Luz PM; Lake JE; Clark JL; Veloso VG; Moreira RI; Cardoso SW; Klausner JD; Grinsztejn B
    BMC Infect Dis; 2014 Jun; 14():322. PubMed ID: 24919778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
    Hammer SM; Vaida F; Bennett KK; Holohan MK; Sheiner L; Eron JJ; Wheat LJ; Mitsuyasu RT; Gulick RM; Valentine FT; Aberg JA; Rogers MD; Karol CN; Saah AJ; Lewis RH; Bessen LJ; Brosgart C; DeGruttola V; Mellors JW;
    JAMA; 2002 Jul; 288(2):169-80. PubMed ID: 12095381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.
    Cuzin L; Pugliese P; Bugnon F; Delpierre C; Cua E; Billaud E; Massip P; Raffi F; Dellamonica P
    HIV Med; 2005 Nov; 6(6):388-95. PubMed ID: 16268820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.
    Sungkanuparph S; Overton ET; Seyfried W; Groger RK; Fraser VJ; Powderly WG
    Clin Infect Dis; 2005 Nov; 41(9):1326-32. PubMed ID: 16206110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
    Paris D; Ledergerber B; Weber R; Jost J; Flepp M; Opravil M; Ruef C; Zimmerli S
    AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1631-8. PubMed ID: 10606086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of antiretroviral third agent virologic durability after initiation of first antiretroviral regimen.
    Varriano B; Sandler I; Loutfy M; Steinberg S; Smith G; Kovacs C; Brunetta J; Fletcher D; Knox D; Merkley B; Chang B; Tilley D; Acsai M; Crouzat F
    Int J STD AIDS; 2019 Jun; 30(7):680-688. PubMed ID: 31042101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of virologic outcome among people living with HIV who continue a protease inhibitor-based antiretroviral regimen following virologic failure with no or limited resistance.
    Salata RA; Grinsztejn B; Ritz J; Collier AC; Hogg E; Gross R; Godfrey C; Kumarasamy N; Kanyama C; Mellors JW; Wallis CL; Hughes MD;
    AIDS Res Ther; 2023 Jan; 20(1):3. PubMed ID: 36604746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens.
    Zheng Y; Hughes MD; Lockman S; Benson CA; Hosseinipour MC; Campbell TB; Gulick RM; Daar ES; Sax PE; Riddler SA; Haubrich R; Salata RA; Currier JS
    Clin Infect Dis; 2014 Sep; 59(6):888-96. PubMed ID: 24842909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure.
    Li JZ; Paredes R; Ribaudo HJ; Svarovskaia ES; Kozal MJ; Hullsiek KH; Miller MD; Bangsberg DR; Kuritzkes DR
    AIDS; 2012 Jan; 26(2):185-92. PubMed ID: 22179227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants.
    Prendergast A; Mphatswe W; Tudor-Williams G; Rakgotho M; Pillay V; Thobakgale C; McCarthy N; Morris L; Walker BD; Goulder P
    AIDS; 2008 Jul; 22(11):1333-43. PubMed ID: 18580613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of single and boosted protease inhibitor versus nonnucleoside reverse transcriptase inhibitor-containing cART regimens in antiretroviral-naïve patients starting cART after January 1, 2000.
    Mocroft ; Horban ; Clumeck ; Stellbrink ; Monforte dA; Zilmer ; Kirk ; Gatell ; Phillips ; Lundgren ;
    HIV Clin Trials; 2006; 7(6):271-84. PubMed ID: 17208897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of virologic failure in HIV-1-infected patients starting highly active antiretroviral therapy in Porto Alegre, Brazil.
    Tuboi SH; Harrison LH; Sprinz E; Albernaz RK; Schechter M
    J Acquir Immune Defic Syndr; 2005 Nov; 40(3):324-8. PubMed ID: 16249707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
    Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
    BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher rates of viral suppression with nonnucleoside reverse transcriptase inhibitors compared to single protease inhibitors are not explained by better adherence.
    Weiser SD; Guzman D; Riley ED; Clark R; Bangsberg DR
    HIV Clin Trials; 2004; 5(5):278-87. PubMed ID: 15562368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa.
    Nachega JB; Hislop M; Nguyen H; Dowdy DW; Chaisson RE; Regensberg L; Cotton M; Maartens G
    J Acquir Immune Defic Syndr; 2009 May; 51(1):65-71. PubMed ID: 19282780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pattern and predictors of immunologic recovery in human immunodeficiency virus-infected children receiving non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy.
    Puthanakit T; Kerr S; Ananworanich J; Bunupuradah T; Boonrak P; Sirisanthana V
    Pediatr Infect Dis J; 2009 Jun; 28(6):488-92. PubMed ID: 19504731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.